The ARK Genomic Revolution ETF (ARKG) has rebounded in the past five weeks, partially offsetting negative performance and outflows experienced since the rotation to cyclicals began in February 2021. A top performer in the health and biotech equities ETF category, ARKG has returned 30.56% over one month and has seen $114 million in net inflows [...] The post Everything Advisors Need to Know About ARKG’s Q2 Performance appeared first on ETF Trends .